Clinical practice guidelines and re-imbursement schedules vary in the recommended timing of FDGPET/CT in the diagnostic evaluation of suspected or conformed lung cancer. The aim was to estimate the probability of requiring more than one invasive test to complete diagnosis and staging in non-small cell lung cancer if FDG-PET/CT was used prior to initial biopsy (FDG-PET/CT First) compared to current Australian funding criteria (CT First). |